# ulcerative colitis (UC) - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: DISEASE-STATE
- Tissue / sample source: colonic mucosal tissue
- Comparison or endpoint: ulcerative colitis versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: 478acec7ab00f0e9bda085b6ecab7aa16a2bc8aa5cde3f2ba8fb71b2af94f79a
- Response HTTP status: 200
- Prompt tokens: 34001
- Completion tokens: 14702
- Reasoning tokens: 0
- Total tokens: 48703
- API requests reported: 3
- Elapsed seconds: 97.128
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1095.213
- Question handoff seconds: 1109.559
- Final benchmark system: E2seq; file rank 2/5; original repeat 3; model vendor: DeepSeek

---
# Multidimensional Interpretation of Ulcerative Colitis Transcriptomic Data

## 1. Overall Biological Interpretation

This dataset, derived from colonic mucosal tissue comparing ulcerative colitis (UC) to healthy controls, reveals a striking and coherent transcriptional signature of active mucosal inflammation with concurrent loss of normal epithelial differentiation and metabolic function. The 100 selected genes (60 downregulated, 40 upregulated) all pass stringent FDR thresholds (FDR ≤ 3.76e-10 for the least significant gene), providing a highly robust statistical foundation.

The dominant pattern is **dual-directional**: a strong upregulation of innate immune, antimicrobial, and tissue-remodeling programs (DUOX2, DUOXA2, LCN2, S100A8, S100P, CHI3L1, MMP3, CXCL1/2/3, SLC6A14, REG4), occurring simultaneously with a profound downregulation of genes involved in normal colonocyte function, including water transport (AQP7, AQP8), bile acid/solute transport (SLC51A, ABCG2, ABCB11), drug/xenobiotic metabolism (CYP2B6, CYP2B7P, UGT2A3, G6PC, HMGCS2), and brush-border enzyme activity (MEP1B, GBA3). This pattern is consistent with the well-established concept of **loss of absorptive/secretory epithelial differentiation** in inflamed UC mucosa, accompanied by a **reactive, stress-induced epithelial and innate immune response**.

The directionality is biologically coherent: essentially all classical pro-inflammatory, antimicrobial, and matrix-degrading genes are upregulated, while essentially all metabolic, transport, and differentiation markers are downregulated. This "on-off" switch between inflammatory and homeostatic programs is the central biological message of this dataset.

---

## 2. Core Biological Programs

### Program 1: Innate Immune / Neutrophil Chemokine Signaling
- **Direction:** Upregulated
- **Supporting genes:** CXCL1 (log2FC=3.46), CXCL2 (2.80), CXCL3 (2.33), S100A8 (3.80), LCN2 (2.67), CHI3L1 (4.59), S100P (1.77), PI3 (2.21), IRAK3 (1.78)
- **Pathway:** KEGG IL-17 signaling pathway; Hallmark IL-6/JAK-STAT3 signaling; Reactome Chemokine receptors bind chemokines
- **Rationale:** The coordinate upregulation of three CXCL chemokines (CXCL1, CXCL2, CXCL3) that share the CXCR2 receptor, together with the alarmin S100A8, the antimicrobial peptide LCN2, and the chitinase-like protein CHI3L1, indicates an active neutrophil-recruiting and neutrophil-activating program. These genes are downstream of NF-κB and IL-17 signaling and are canonical markers of active UC inflammation.
- **Evidence strength:** Strong. Multiple independent genes, all highly significant (FDR from 1.15e-15 to 4.43e-11), with well-established roles in UC and IBD pathogenesis in the literature. STRING records indicate pathway co-membership among CXCL1/2/3 (shared CXCR2 receptor).
- **Limitations:** These genes are not UC-specific; they are shared across many inflammatory conditions. The relative contribution of epithelial versus myeloid cells cannot be resolved from bulk tissue data.

### Program 2: Reactive Oxygen Species (ROS) / Antimicrobial Defense
- **Direction:** Upregulated
- **Supporting genes:** DUOX2 (4.67), DUOXA2 (2.89), SLC6A14 (4.85), LCN2 (2.67), S100A8 (3.80), REG4 (2.05)
- **Pathway:** Reactome Detoxification of Reactive Oxygen Species; KEGG IL-17 signaling (DUOX2)
- **Rationale:** DUOX2 (dual oxidase 2) and its maturation factor DUOXA2 form the major H₂O₂-generating system in the colonic epithelium, driven by microbial signals and inflammatory cytokines. The extreme upregulation of SLC6A14 (an amino acid transporter, log2FC=4.85, FDR=8.07e-39) is notable — it is an established UC marker associated with epithelial stress responses. LCN2 and S100A8 are antimicrobial/calprotectin components. This program represents a coordinated epithelial antimicrobial response.
- **Evidence strength:** Strong for DUOX2/DUOXA2/LCN2/S100A8 as a coherent group; SLC6A14 is a well-replicated UC biomarker in the literature (multiple independent cohorts), though its mechanistic link to ROS is indirect.
- **Limitations:** The link between SLC6A14 and the ROS program is putative; it may better fit a metabolic/transport program.

### Program 3: Loss of Epithelial Differentiation and Transport Function
- **Direction:** Downregulated
- **Supporting genes:** AQP8 (-4.42), SLC51A (-3.71), ABCG2 (-2.92), CYP2B6 (-2.78), UGT2A3 (-2.68), AQP7 (-2.32), MEP1B (-2.99), GBA3 (-3.00), HMGCS2 (-3.45), SLC16A1 (-2.38), ABCB11 (-1.15)
- **Pathway:** KEGG Bile secretion; Reactome Passive transport by Aquaporins; GO Fluid Transport (GO:0042044), Water Transport (GO:0006833), Carboxylic Acid Transport (GO:0046942)
- **Rationale:** This is one of the most striking and coherent patterns in the dataset: near-universal downregulation of transporters, channels, and metabolic enzymes characteristic of the healthy differentiated colonocyte. AQP8 (water channel, log2FC=-4.42) and AQP7 (glycerol/water channel) are both downregulated, consistent with loss of water-handling capacity. Bile acid transporters (SLC51A, ABCB11), xenobiotic efflux pumps (ABCG2), phase I/II drug metabolism enzymes (CYP2B6, UGT2A3), and the ketogenic enzyme HMGCS2 are all suppressed. This pattern reflects dedifferentiation or loss of mature absorptive colonocytes in inflamed mucosa.
- **Evidence strength:** Strong. The coordinated downregulation of multiple independent transporter/metabolic genes with extremely low FDRs is highly robust. The GO annotations for fluid/water/carboxylic acid transport directly match this gene set.
- **Limitations:** Whether this reflects (a) loss of mature colonocytes, (b) replacement by immature/regenerative epithelium, or (c) transcriptional repression in surviving cells cannot be distinguished from bulk transcriptomics. This is a composition-sensitive signal.

### Program 4: Tissue Remodeling and Extracellular Matrix Turnover
- **Direction:** Upregulated
- **Supporting genes:** MMP3 (4.64), TNC (2.58), TGM2 (1.91), PDPN (2.54), TIMP1 (1.97), CDH3 (2.29), PRRX1 (2.91), FILIP1L (1.86)
- **Pathway:** KEGG Rheumatoid arthritis (MMP3, CXCL1, CXCL2, IL1RN); Reactome Extracellular matrix organization
- **Rationale:** The dramatic upregulation of MMP3 (matrix metalloproteinase 3, log2FC=4.64), the matrix protein TNC (tenascin-C), and the crosslinking enzyme TGM2 indicates active extracellular matrix degradation and remodeling. TIMP1 (the MMP inhibitor) is also upregulated, suggesting a dynamic balance between proteolysis and inhibition. PDPN (podoplanin), CDH3 (P-cadherin), and PRRX1 are markers of mesenchymal/stromal activation and epithelial-mesenchymal plasticity.
- **Evidence strength:** Moderate-to-strong. MMP3 and TNC are well-established UC/IBD markers. The grouping of PRRX1, PDPN, and CDH3 suggests stromal/epithelial activation but the relationships among them are inferred, not demonstrated.
- **Limitations:** The MMP3/TIMP1 balance is complex; upregulation of both does not tell us net proteolytic activity. Stromal versus epithelial contributions cannot be separated in bulk tissue.

### Program 5: Immune Regulation and Checkpoint Signaling
- **Direction:** Upregulated
- **Supporting genes:** CTLA4 (2.62), SOCS3 (2.79), IL1RN (2.88), DAPP1 (2.20), IFI16 (1.39), CD55 (2.04)
- **Pathway:** Reactome Immune System; KEGG IL-17 signaling (SOCS3); GO biological process (immune regulation)
- **Rationale:** The upregulation of CTLA4 (cytotoxic T-lymphocyte-associated protein 4, an immune checkpoint), SOCS3 (a negative regulator of JAK/STAT signaling), and IL1RN (the IL-1 receptor antagonist) indicates an active **counter-regulatory** or negative-feedback response to inflammation. IL1RN and SOCS3 are classic negative feedback inhibitors; CTLA4 suggests T-cell activation with concurrent checkpoint engagement. DAPP1 is a B-cell adaptor, and IFI16 is an interferon-inducible DNA sensor.
- **Evidence strength:** Moderate. These genes are individually significant and biologically coherent as negative regulators, but they are fewer in number and more functionally diverse than the other programs.
- **Limitations:** IL1RN upregulation in UC is well documented but its net effect depends on the IL-1/IL-1RN ratio. CTLA4 expression could reflect infiltrating regulatory T cells or activated T cells; cell-type deconvolution would be needed.

---

## 3. Key Genes and Interaction Modules

### 1. SLC6A14 (upregulated, log2FC=4.85, FDR=8.07e-39)
- **Role:** Amino acid transporter; the single most significant gene in the dataset. Well-replicated UC biomarker in multiple independent cohorts from the literature. Its function in UC is not fully defined but may relate to epithelial stress responses, amino acid uptake for repair, or altered tryptophan/arginine metabolism.
- **Relationships:** Pathway co-membership with other solute carriers (SLC16A1, SLC23A1/3, SLC51A) in the broad "carboxylic acid transport" GO category, but no direct interaction evidence with those genes.

### 2. DUOX2 / DUOXA2 module (upregulated, log2FC=4.67 and 2.89)
- **Role:** Epithelial ROS-generating system; DUOXA2 is the maturation factor required for DUOX2 function. This is a **direct functional partnership**: DUOXA2 is required for DUOX2's trafficking to the plasma membrane and catalytic activity. This is a direct physical/functional interaction, not merely co-expression.
- **Relationships:** DUOX2 is induced by IL-17 and microbial signals; its upregulation is consistent with the IL-17 pathway signal in this dataset.

### 3. CXCL1/CXCL2/CXCL3 module (upregulated, log2FC=3.46/2.80/2.33)
- **Role:** Neutrophil chemoattractants sharing the CXCR2 receptor. STRING records indicate pathway co-membership; OmniPath/CellTalkDB records list CXCL1/CXCL2 as ligands for ADRA2A (putative). These are **pathway co-members** (shared receptor/ligand system), not direct physical interactors with each other.
- **Relationships:** Co-regulated by NF-κB and IL-17; co-expression in inflamed mucosa is expected.

### 4. MMP3 / TIMP1 module (upregulated, log2FC=4.64 and 1.97)
- **Role:** MMP3 is a major matrix-degrading enzyme; TIMP1 is its endogenous inhibitor. STRING records indicate a direct physical interaction between MMP3 and TIMP1 (TIMP1 inhibits MMP3 by direct binding). This is one of the few **direct physical interactions** supported by interaction databases.
- **Relationships:** The simultaneous upregulation suggests active remodeling with attempted inhibition; net proteolytic activity cannot be inferred from mRNA alone.

### 5. AQP7 / AQP8 module (downregulated, log2FC=-2.32 and -4.42)
- **Role:** Water/glycerol channels. STRING records show interaction evidence between AQP7 and AQP8 (likely co-membership in the aquaporin family and potential hetero-oligomerization, though direct physical interaction in colon is not established). Reactome lists both in "Passive transport by Aquaporins."
- **Relationships:** Pathway co-membership in water transport; the coordinated downregulation indicates loss of epithelial water-handling capacity.

### 6. S100A8 / S100P / S100 family (upregulated, log2FC=3.80 and 1.77)
- **Role:** S100A8 (calprotectin subunit) is a canonical fecal biomarker for UC activity. S100P is a related S100 family member. STRING records suggest CDH1 (E-cadherin) as a potential interaction partner for S100A8 (putative/indirect).
- **Relationships:** Co-expression as alarmins/calgranulins in myeloid and stressed epithelial cells.

### 7. CTLA4 (upregulated, log2FC=2.62)
- **Role:** Immune checkpoint receptor on T cells. Its upregulation indicates T-cell activation with concurrent negative regulation. This is clinically relevant given the use of anti-CTLA4 therapy in cancer and the risk of colitis as an immune-related adverse event.
- **Relationships:** Likely reflects infiltrating T cells; no direct interaction with the epithelial genes in this dataset.

### 8. SLC51A / ABCG2 / ABCB11 module (all downregulated, log2FC=-3.71/-2.92/-1.15)
- **Role:** Bile acid and xenobiotic transporters. SLC51A (OSTα) and ABCB11 (BSEP) are bile acid transporters; ABCG2 is an efflux pump. Their coordinate downregulation suggests impaired bile acid handling and detoxification in UC mucosa.
- **Relationships:** Pathway co-membership in KEGG Bile secretion; no evidence of direct physical interaction among these three.

### 9. SOCS3 / IL1RN module (upregulated, log2FC=2.79 and 2.88)
- **Role:** Negative regulators of inflammatory signaling (SOCS3 inhibits JAK/STAT; IL1RN antagonizes IL-1 receptor). TRRUST records may support regulatory relationships with NF-κB pathway members (regulatory, not physical).
- **Relationships:** Regulatory interaction — both are induced by the pathways they inhibit (negative feedback).

### 10. TNC / TGM2 / PDPN module (upregulated, log2FC=2.58/1.91/2.54)
- **Role:** Extracellular matrix and stromal activation markers. STRING records indicate TGM2 and TNC as potential interactors with ITGB1 (integrin β1), suggesting **indirect/putative** relationships through integrin signaling. These are markers of tissue remodeling and fibrosis.
- **Relationships:** Pathway co-membership in matrix organization; direct physical interactions are not established among these three.

---

## 4. Validation Priorities

### Priority 1: Cell-type deconvolution / composition check
- **Classification:** Confounding or composition check
- **Why:** The most significant risk to interpretation is that the "epithelial differentiation loss" program (Program 3) may reflect a relative decrease in epithelial cell fraction (due to immune cell infiltration) rather than genuine transcriptional reprogramming of colonocytes.
- **Current evidence:** Bulk tissue transcriptomics with 60 downregulated genes enriched for transporters/metabolic enzymes.
- **External evidence:** Literature consistently shows immune cell infiltration in UC; single-cell studies show both loss of mature colonocyte populations and transcriptional changes in surviving epithelium.
- **Next step:** Single-cell RNA-seq or computational deconvolution (e.g., CIBERSORTx, MuSiC) on the same cohort; or immunohistochemistry for AQP8, MEP1B, and CDH1 to confirm protein-level loss.
- **Status:** Supported hypothesis (that composition contributes); the direction of the effect is established, the mechanism is not.

### Priority 2: DUOX2/DUOXA2 functional validation
- **Classification:** Mechanistic hypothesis
- **Why:** The DUOX2/DUOXA2 module is the clearest epithelial-specific ROS program and is highly significant.
- **Current evidence:** Both genes strongly upregulated (log2FC 4.67 and 2.89).
- **External evidence:** DUOX2 is induced by IL-17 and microbial products; its role in IBD is supported by multiple studies, though whether its ROS production is protective (antimicrobial) or pathogenic (tissue damage) remains debated.
- **Next step:** Measure H₂O₂ production in patient-derived organoids or intestinal epithelial cell lines stimulated with UC-relevant cytokines; assess DUOX2 inhibition effects on epithelial barrier function.
- **Status:** Supported hypothesis.

### Priority 3: SLC6A14 as a diagnostic/activity biomarker
- **Classification:** Biomarker
- **Why:** SLC6A14 is the most significant gene in the dataset (FDR=8.07e-39) and is well-replicated in the literature as a UC marker.
- **Current evidence:** Extreme upregulation (log2FC=4.85) in this cohort.
- **External evidence:** Multiple independent studies have reported SLC6A14 upregulation in UC; it has been proposed as a fecal or mucosal biomarker.
- **Next step:** Validate in an independent cohort (e.g., qPCR or RNA-seq on a separate UC/control set); test correlation with endoscopic disease activity; assess whether it outperforms or complements calprotectin.
- **Status:** Supported hypothesis for association; external statistical validation was not performed in this analysis.

### Priority 4: MMP3/TIMP1 balance and tissue remodeling
- **Classification:** Mechanistic hypothesis
- **Why:** MMP3 is among the most upregulated genes (log2FC=4.64) and is a direct effector of matrix degradation; understanding the MMP3/TIMP1 balance is critical for fibrosis and tissue destruction.
- **Current evidence:** Both MMP3 and TIMP1 upregulated; direct physical interaction between MMP3 and TIMP1 is supported by interaction databases.
- **External evidence:** MMP3 is elevated in UC mucosa and serum; MMP inhibitors have been explored but not clinically established in IBD.
- **Next step:** Zymography or activity assays on mucosal biopsies to measure net MMP3 proteolytic activity; correlate with histological damage scores.
- **Status:** Supported hypothesis.

### Priority 5: CTLA4 and immune checkpoint involvement
- **Classification:** Therapeutic target (or biomarker for checkpoint-related colitis)
- **Why:** CTLA4 upregulation in UC mucosa has implications for both UC pathogenesis (T-cell regulation) and for understanding checkpoint-inhibitor-induced colitis.
- **Current evidence:** CTLA4 upregulated (log2FC=2.62, FDR=1.11e-10).
- **External evidence:** Anti-CTLA4 therapy (ipilimumab) causes colitis as a major immune-related adverse event; CTLA4 polymorphisms have been associated with UC susceptibility in genetic studies.
- **Note:** The existence of anti-CTLA4 drugs does not imply that targeting CTLA4 is therapeutic for UC — in fact, anti-CTLA4 would be predicted to worsen UC. The therapeutic hypothesis here is the opposite: CTLA4 engagement may be a protective counter-regulatory mechanism.
- **Next step:** Flow cytometry or single-cell analysis to identify which T-cell subsets express CTLA4; test whether CTLA4-Ig (abatacept) has efficacy in UC models.
- **Status:** Exploratory hypothesis for therapeutic relevance; association with UC is established.

---

## 5. Evidence Grounding

| Program/Gene | Direct Input Evidence | Pathway/Ontology | Protein Interaction/Regulatory | Disease Association | Expression/Tissue | Genetic/Clinical | Drug/Therapeutic | Literature |
|---|---|---|---|---|---|---|---|---|
| Innate immune/CXCL program | Strong (multiple genes, very low FDR) | KEGG IL-17, Rheumatoid arthritis | CXCR2 co-membership (STRING) | Well-established (UC/IBD) | Consistent (inflamed colon) | GWAS: CXCL genes not primary UC loci | Anti-CXCR2 explored in other diseases | Extensive UC literature |
| DUOX2/ROS program | Strong (DUOX2, DUOXA2) | Reactome ROS detoxification; KEGG IL-17 | DUOXA2-DUOX2 direct functional partnership | Established (IBD epithelial ROS) | Consistent | Not a primary GWAS locus | No approved UC drug targeting DUOX2 | Multiple IBD studies |
| Epithelial differentiation loss | Strong (many transporters, all down) | KEGG Bile secretion; GO transport terms | Pathway co-membership only | Consistent with UC epithelial damage | Consistent | ABCG2/ABCB11 have genetic variants but not UC-specific | N/A | Literature on colonocyte dedifferentiation |
| Tissue remodeling | Strong (MMP3, TNC) | KEGG Rheumatoid arthritis | MMP3-TIMP1 direct physical interaction (STRING) | Established (MMP3 in UC) | Consistent | MMP3 polymorphisms associated with IBD | MMP inhibitors not approved for UC | Extensive |
| Immune regulation | Moderate (CTLA4, SOCS3, IL1RN) | Reactome Immune System | SOCS3 regulatory (JAK/STAT feedback) | CTLA4: genetic association with UC; IL1RN: anakinra target | Consistent | CTLA4 SNPs in UC GWAS | Anakinra (IL1RN) not approved for UC; abatacept (CTLA4-Ig) in trials | Literature supports counter-regulation |

**Independence of evidence sources:** The pathway annotations (Reactome, KEGG, GO), interaction databases (STRING, IntAct), and literature records are **not fully independent** — they draw on overlapping underlying publications and annotation pipelines. The strongest independent evidence is (a) the direct statistical results from this dataset and (b) the replication of key genes (SLC6A14, DUOX2, MMP3, S100A8, AQP8) in published independent UC cohorts. However, **external statistical validation was not performed** in this analysis — no independent-cohort statistics were supplied.

---

## 6. Limitations and Alternative Explanations

### 1. Cell-composition effects (most important)
The bulk tissue transcriptome reflects a mixture of epithelial, immune, stromal, and endothelial cells. The downregulation of epithelial transporters (AQP8, SLC51A, HMGCS2) could reflect (a) loss of differentiated colonocytes, (b) dilution by infiltrating immune cells, or (c) transcriptional repression. The upregulation of immune genes (CTLA4, DAPP1, CXCLs) could reflect increased immune cell numbers rather than increased per-cell expression. **How to test:** Single-cell RNA-seq; computational deconvolution; immunohistochemistry for key proteins (AQP8, MEP1B).

### 2. Disease severity and treatment exposure
UC is a heterogeneous disease with variable severity and treatment history. The dataset does not specify disease activity, extent, or medication exposure (5-ASA, corticosteroids, biologics, immunomodulators). All of these strongly affect the mucosal transcriptome. The extreme effect sizes (e.g., SLC6A14 log2FC=4.85) suggest active, moderate-to-severe inflammation. **How to test:** Stratify by disease activity (Mayo endoscopic subscore), medication status, and disease extent.

### 3. Duplicate gene/probe handling
The ledger notes 43 duplicated genes/probes (e.g., CYP2B7P|CYP2B6, NAT8B|NAT8, multiple probes for SLC16A1, ETNK1, WDR78). While the ledger marks these as "clean" and the displayed representative rows are consistent, merged gene symbols (e.g., "LOC100290146|IGHV4-31|IGHM|IGHG1|IGH") are ambiguous and could represent probe cross-hybridization rather than true gene expression. **How to test:** Confirm with qPCR or independent RNA-seq; annotate ambiguous probes.

### 4. Association versus causation
This is a cross-sectional disease-state comparison. Upregulation of inflammatory genes could be a cause, consequence, or compensatory response to UC. For example, DUOX2-derived ROS could drive tissue damage or serve a protective antimicrobial function; IL1RN upregulation is likely compensatory. **How to test:** Longitudinal sampling; functional perturbation in animal models or organoids; Mendelian randomization using genetic variants.

### 5. Platform and batch effects
The presence of probe IDs (PROBE_241592_PM_at, PROBE_227140_PM_at, PROBE_235105_PM_at) indicates an Affymetrix microarray platform. Batch effects, array version differences, and normalization choices can influence results, particularly for probes with ambiguous annotation. The very low FDRs suggest robust signal, but cross-platform validation is advisable. **How to test:** Validate top genes by qPCR or RNA-seq in a separate cohort; assess batch structure if metadata are available.

---

## Summary

This dataset provides a statistically robust (all 100 genes at FDR < 3.8e-10) and biologically coherent picture of active UC: a coordinated upregulation of innate immune, antimicrobial, and tissue-remodeling programs alongside a profound loss of differentiated epithelial transport and metabolic function. The most defensible conclusions are: (1) the dual-directional pattern (immune activation up, epithelial function down) is the central biological theme; (2) DUOX2/DUOXA2, CXCL1/2/3, MMP3, and SLC6A14 are the strongest individual signals; and (3) the "epithelial dedifferentiation" interpretation carries the caveat that cell-composition effects cannot be excluded from bulk tissue data. External statistical validation in an independent cohort was not performed and remains a priority, as does single-cell resolution to distinguish transcriptional reprogramming from cell-type shifts.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=21, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 94/100 selected items (records returned); cbioportal 87/100 selected items (records returned); chembl 40/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 51/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 55/100 selected items (partially returned; some queries failed); europepmc 936 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 91/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 85/100 selected items (records returned); humanbase 87/100 selected items (records returned); intact 85/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 45/100 selected items (records returned); opentargets 92/100 selected items (records returned); pubmed 750 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 87/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 88/100 selected items (records returned)
Local databases: gutmgene 8/100 selected items (records returned); hmdb 46/100 selected items (records returned); string 85/100 selected items (records returned); trrust 31/100 selected items (records returned)
